|
Study period
|
---|
Enrolment/allocation
|
Post-allocation
|
Close-out
|
---|
Outpatient clinics
|
CRS-HIPEC
|
3 months after CRS-HIPEC
|
6 months after CRS-HIPEC
|
9 months after CRS-HIPEC
|
12 months after CRS-HIPEC
|
Every 6 months
|
5 years after randomisation
|
---|
Enrolment/allocation
|
Eligibility screen
|
X
| | | | | | | |
Informed consent
|
X
| | | | | | | |
Allocation
|
X
| | | | | | | |
Interventions
|
CRS-HIPEC
| |
X
| | | | | | |
Thoracoabdominal CT
| | |
X
|
X
| |
X
|
X
|
X
|
Questionnaires
|
X
| |
X
|
X
|
X
|
X
|
X
|
X
|
Translational research: blood
|
X
|
Xa
|
X
|
X
| |
X
|
X
|
X
|
Translational research: tissue
| |
X
| | | | | | |
Assessments
|
Baseline characteristics
|
X
| | | | | | | |
Surgical characteristics
| |
X
| | | | | | |
Postoperative morbidity
| |
X
|
X
| | | | | |
Progression-free survival
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Disease-free survival
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Overall survival
| |
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Health-related quality of life
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
Costs
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
X
|
- a1 day before CRS-HIPEC and 7 days after CRS-HIPEC; CRS-HIPEC cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, CT computed tomography